Compare Immunovant Inc. Common Stock (IMVT) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs ThredUp Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.47 (market cap $6.25B), while ThredUp Inc trades at $2.48 (market cap $308.63M). The key difference: Immunovant Inc. Common Stock is far larger — about 20.3× ThredUp Inc's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, ThredUp Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and ThredUp Inc for 29 Days on average.
| IMVT | TDUP | |
|---|---|---|
Market Cap | $6.25B | $308.63M |
Volume | 1,755,411 | 3,024,364 |
Sector | Health | Consumer Cyclical |
52-Week High | $44.96 | $9.41 |
52-Week Low | $17.03 | $2.12 |
Typical Hold Time | 1 Days | 29 Days |
Enterprise Value | $5.35B | $306.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ThredUp (TDUP) trades at $2.35, up 5.86% today, with a bearish technical signal and mixed financials. Revenue grew to $310.81M in 2025, but net losses persist at -$20.21M, though margins improved. Recent news highlights a record Q2 2026 with 17% revenue growth but also a fraud investigation and lowered guidance, causing volatility. Cash flow turned positive in 2025 at $3.09M, but debt-to-asset ratios remain elevated.
Outlook is cautious; analyst consensus is 57% buy, but profitability challenges and legal risks weigh. The stock faces headwinds from promotional pressures and investor skepticism, though expansion into live shopping offers growth potential. Risks include sustained losses, competitive threats, and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
